DOCT.L vs. BTEC.L
DOCT.L (L&G Healthcare Breakthrough UCITS ETF) and BTEC.L (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) are both Health & Biotech Equities funds - DOCT.L tracks the MSCI World/Health Care NR USD while BTEC.L tracks the NASDAQ Biotechnology NET Index. Both are passively managed. Over the past 5 years, DOCT.L returned -3.16%/yr vs 5.87%/yr for BTEC.L. A 0.79 correlation means they provide meaningful diversification when combined. DOCT.L charges 0.49%/yr vs 0.35%/yr for BTEC.L.
Performance
DOCT.L vs. BTEC.L - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, DOCT.L achieves a 6.89% return, which is significantly lower than BTEC.L's 15.22% return.
DOCT.L
- 1D
- 1.46%
- 1M
- 8.05%
- 6M
- 2.37%
- YTD
- 6.89%
- 1Y
- 36.46%
- 3Y*
- 8.21%
- 5Y*
- -3.16%
- 10Y*
- —
BTEC.L
- 1D
- 0.68%
- 1M
- 9.55%
- 6M
- 13.18%
- YTD
- 15.22%
- 1Y
- 50.31%
- 3Y*
- 16.99%
- 5Y*
- 5.87%
- 10Y*
- —
DOCT.L vs. BTEC.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|---|
DOCT.L L&G Healthcare Breakthrough UCITS ETF | 6.89% | 24.90% | 1.96% | -1.16% | -33.86% | 0.19% | 66.94% | 10.00% |
BTEC.L iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) | 15.22% | 32.96% | -2.04% | 6.22% | -11.92% | -0.49% | 27.40% | 10.88% |
Correlation
The correlation between DOCT.L and BTEC.L is 0.70, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.70 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.73 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.77 |
Correlation (All Time) Calculated using the full available price history since Jun 26, 2019 | 0.79 |
The correlation between DOCT.L and BTEC.L has been stable across timeframes, ranging from 0.70 to 0.79 - a consistent structural relationship.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
DOCT.L vs. BTEC.L — Risk / Return Rank
DOCT.L
BTEC.L
DOCT.L vs. BTEC.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for L&G Healthcare Breakthrough UCITS ETF (DOCT.L) and iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (BTEC.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| DOCT.L | BTEC.L | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.73 | ||
| Sortino ratioReturn per unit of downside risk | -0.82 | ||
| Omega ratioGain probability vs. loss probability | 1.29 | 1.39 | -0.10 |
| Calmar ratioReturn relative to maximum drawdown | 2.13 | 6.22 | -4.09 |
| Martin ratioReturn relative to average drawdown | 5.00 | 19.15 | -14.15 |
Loading charts...
Drawdowns
DOCT.L vs. BTEC.L - Drawdown Comparison
The maximum DOCT.L drawdown since its inception was -57.54%, which is greater than BTEC.L's maximum drawdown of -38.42%. Use the drawdown chart below to compare losses from any high point for DOCT.L and BTEC.L.
Loading charts...
Drawdown Indicators
| DOCT.L | BTEC.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -57.54% | -38.42% | -19.12% |
Max Drawdown (1Y)Largest decline over 1 year | -17.02% | -7.94% | -9.08% |
Max Drawdown (3Y)Largest decline over 3 years | -28.75% | -26.74% | -2.01% |
Max Drawdown (5Y)Largest decline over 5 years | -55.80% | -38.42% | -17.38% |
Current DrawdownCurrent decline from peak | -25.19% | -3.87% | -21.32% |
Average DrawdownAverage peak-to-trough decline | -28.91% | -13.22% | -15.69% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.27% | 2.58% | +4.69% |
Volatility
DOCT.L vs. BTEC.L - Volatility Comparison
L&G Healthcare Breakthrough UCITS ETF (DOCT.L) has a higher volatility of 6.81% compared to iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (BTEC.L) at 5.91%. This indicates that DOCT.L's price experiences larger fluctuations and is considered to be riskier than BTEC.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| DOCT.L | BTEC.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.81% | 5.91% | +0.90% |
Volatility (6M)Calculated over the trailing 6-month period | 16.61% | 15.67% | +0.94% |
Volatility (1Y)Calculated over the trailing 1-year period | 21.54% | 20.42% | +1.12% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 24.12% | 21.39% | +2.73% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 24.67% | 22.37% | +2.30% |
DOCT.L vs. BTEC.L - Expense Ratio Comparison
DOCT.L has a 0.49% expense ratio, which is higher than BTEC.L's 0.35% expense ratio.
Dividends
DOCT.L vs. BTEC.L - Dividend Comparison
Neither DOCT.L nor BTEC.L has paid dividends to shareholders.
Frequently Asked Questions
DOCT.L and BTEC.L have a correlation of 0.70, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, BTEC.L is cheaper at 0.35% per year. The better choice depends on whether you care most about return, fees, risk, or income.
BTEC.L is cheaper with a 0.35% expense ratio, compared with 0.49% for DOCT.L.
DOCT.L tracks MSCI World/Health Care NR USD, while BTEC.L tracks NASDAQ Biotechnology NET Index. They also come from different issuers: Legal & General and iShares. Their fees differ too: 0.49% for DOCT.L and 0.35% for BTEC.L.
Find the right allocation for DOCT.L and BTEC.L
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer